PARIS: French pharmaceutical giant Sanofi and struggling US rival Novavax announced on Friday (May 10) an alliance to sell a COVID-19 vaccine and develop another that combines with a flu shot. Under a licensing deal worth up to US$1.2 billion, the companies will co-commercialise Novavax's COVID-19 vaccine
